ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 29, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 29, 2011
FDA Publishes Guidance on Marketed Unapproved Drugs
By Erik Greb
FDA has published a guidance on Marketed Unapproved Drugs—Compliance Policy Guide, which describes the agency's enforcement priorities with regard to products that lack regulatory approval or that are not marketed in accordance with the over-the-counter drug review.
New FDA Guidance on User Fee Waivers, Reductions, and Refunds
By Amy Ritter
FDA has issued a guidance titled User Fee Waivers, Reductions and Refunds for Drug and Biological Products that outlines FDA's policies for issuing waivers, refunds or reductions in prescription drug user fees.
EMA Committee Offers Positive Opinion on New Drugs, Moves Forward with Key Concept Papers
By Stephanie Sutton
The latest meeting of the EMA's Committee for Medicinal Products for Human Use has concluded with more than 15 positive opinions for new and generic drugs and the adoption of key concept papers.
Week of Sept. 26, 2011: BMS Collaborates With Ambryx; Merck & Co. Opens New R&D Center; Teva Acquires Joint Venture Interest; and More.
Week of Sept. 26, 2011: BMS collaborates with Ambryx; Merck & Co. opens new R&D center; Teva acquires joint venture interest; and More.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here